WO1998010786A3 - Composition pharmaceutique pour le traitement du syndrome x de reaven - Google Patents

Composition pharmaceutique pour le traitement du syndrome x de reaven Download PDF

Info

Publication number
WO1998010786A3
WO1998010786A3 PCT/IL1997/000301 IL9700301W WO9810786A3 WO 1998010786 A3 WO1998010786 A3 WO 1998010786A3 IL 9700301 W IL9700301 W IL 9700301W WO 9810786 A3 WO9810786 A3 WO 9810786A3
Authority
WO
WIPO (PCT)
Prior art keywords
syndrome
reaven
treatment
pharmaceutical composition
analogs
Prior art date
Application number
PCT/IL1997/000301
Other languages
English (en)
Other versions
WO1998010786A2 (fr
Inventor
Yarom Cohen
Original Assignee
Yarom Cohen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11925096A external-priority patent/IL119250A/xx
Priority claimed from IL11940396A external-priority patent/IL119403A/en
Application filed by Yarom Cohen filed Critical Yarom Cohen
Priority to AU41339/97A priority Critical patent/AU4133997A/en
Publication of WO1998010786A2 publication Critical patent/WO1998010786A2/fr
Publication of WO1998010786A3 publication Critical patent/WO1998010786A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins

Abstract

L'invention concerne une composition pharmaceutique comprenant, en tant que principe actif, un composé choisi parmi la somatostatine ou un de ses analogues, le diazoxyde ou un de ses analogues, le cyclothiazidéor ou un de ses analogues et la metformine, pour le traitement du syndrome X de Raeven (également appelé syndrome d'hyperinsulinémie ou 'quartet meurtrier').
PCT/IL1997/000301 1996-09-12 1997-09-10 Composition pharmaceutique pour le traitement du syndrome x de reaven WO1998010786A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU41339/97A AU4133997A (en) 1996-09-12 1997-09-10 Pharmaceutical composition for the treatment of syndrome x of reaven

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL11925096A IL119250A (en) 1996-09-12 1996-09-12 Pharmaceutical composition for the treatment of syndrome x of reaven
IL119250 1996-09-12
IL11940396A IL119403A (en) 1996-10-10 1996-10-10 Pharmaceutical composition for the treatment of syndrome x of reaven
IL119403 1996-10-10

Publications (2)

Publication Number Publication Date
WO1998010786A2 WO1998010786A2 (fr) 1998-03-19
WO1998010786A3 true WO1998010786A3 (fr) 1998-08-27

Family

ID=26323304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL1997/000301 WO1998010786A2 (fr) 1996-09-12 1997-09-10 Composition pharmaceutique pour le traitement du syndrome x de reaven

Country Status (2)

Country Link
AU (1) AU4133997A (fr)
WO (1) WO1998010786A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0981364B1 (fr) * 1997-05-13 2006-03-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Procede et compositions pour traiter l'hyperlipidemie
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
EP0981363B1 (fr) 1997-05-13 2003-07-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Agonistes de somatostatine servant a la reduction du poids corporel
ES2216290T3 (es) * 1997-05-13 2004-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatina y agonistas de la somatostatina para el tratamiento de insensibilidad a la insulina y de sindrome x.
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
EP1291022A1 (fr) * 1998-07-30 2003-03-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Procédés d'utilisation du lanréotide, un analogue de la somatostatine
EP1100532A2 (fr) * 1998-07-30 2001-05-23 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Procedes d'utilisation d'un analogue de somatostatine
US6150333A (en) * 1998-07-30 2000-11-21 Biomeasure, Inc. Methods of using a somatostatin analogue
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
ES2306766T3 (es) 2001-03-08 2008-11-16 The Administrators Of The Tulane Educational Fund Antagonistas de somatostatina.
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
EP2404605B1 (fr) 2004-08-25 2015-04-22 Essentialis, Inc. Formulations pharmaceutiques d'activateurs de canaux potassiques ATP et leurs utilisations
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
EP2404604B1 (fr) 2006-01-05 2019-02-06 Essentialis, Inc. Sels d'ouverture de canal ATP du potassium et leurs utilisations
US20120053172A1 (en) * 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
EP2819675A4 (fr) 2012-02-27 2015-07-22 Essentialis Inc Sels d'ouvreurs des canaux potassiques atp et leurs utilisations
WO2016038565A1 (fr) * 2014-09-14 2016-03-17 Tel Hashomer Medical Research Infrastructure And Services Ltd. Ligands synthétiques des récepteurs de la somatostatine
AU2015346196B2 (en) 2014-11-14 2019-01-31 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100153A (en) * 1977-05-11 1978-07-11 American Home Products Corporation (D-Trp5)-somatostatin and analogues thereof
US4159263A (en) * 1977-05-11 1979-06-26 American Home Products Corporation (D-Ala5)-somatostatin and analogues thereof
EP0374089A2 (fr) * 1988-11-11 1990-06-20 Sandoz Ag Utilisation de dérivés de la somatostatine comme agents protecteurs des poumons

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100153A (en) * 1977-05-11 1978-07-11 American Home Products Corporation (D-Trp5)-somatostatin and analogues thereof
US4159263A (en) * 1977-05-11 1979-06-26 American Home Products Corporation (D-Ala5)-somatostatin and analogues thereof
EP0374089A2 (fr) * 1988-11-11 1990-06-20 Sandoz Ag Utilisation de dérivés de la somatostatine comme agents protecteurs des poumons

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BLUMING A.Z. ET AL: "Successful treatment of unstable angina in malignant carcinoid syndrome using the long acting somatostatin analogue SMS 201-995 (sandostatin)", THE AMERICAN JOURNAL OF MEDICINE, vol. 85, 1988, pages 872 - 874, XP002053036 *
BOYLE P.J. ET AL: "Octeotride reverses hyperinsulinaemia and prevents hypoglycemia induced by sulfonilurea overdoses", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 76, no. 3, 1993, pages 752 - 756, XP002053033 *
CARRETTA, R. ET AL: "Reduction of blood pressure in obese hyperinsulinaemic hypertensive patients during somatostatin infusion", JOURNAL OF HYPERTENSION SUPPLEMENT, vol. 7, 1989, pages s196 - s197, XP002053034 *
GUILLAUME G. ET AL: "Syndrome X et médecine générale", REVUE MEDICALE DE BRUXELLES, vol. 16, no. 2, 1995, XP002053039 *
KIRK, J.M.W. ET AL: "Somatostatin analogue in short term management of hyperinsulinism", ARCHIVES OF DISEASE IN CHILDHOOD, vol. 63, no. 12, 1988, pages 14931494, XP002053035 *
PHILLIPS R.E. ET AL: "Effectiveness of SMS 201-995, a synthetic, long-acting somatostatin analogue, in treatment of quinine-induced hyperinsulinaemia", LANCET THE, vol. 1, 1986, LONDON GB, pages 713 - 715, XP002053032 *
RAYNOR K ET AL: "Characterization of cloned somatostatin receptors SSTR4 and SSTR5", MOLECULAR PHARMACOLOGY, vol. 44, no. 2, August 1993 (1993-08-01), pages 385 - 392, XP000644418 *
RAYNOR K ET AL: "Cloned somatostatin receptors: identification of subtype-selective peptides and demostration of high affinity binding of linear peptides", MOLECULAR PHARMACOLOGY, vol. 43, no. 6, June 1993 (1993-06-01), pages 838 - 844, XP000676382 *
SIRTORI C.R. ET AL: "Re-evaluation of a biguanide, Metformin: mechanism of action and tolerability", PHARMACOLOGICAL RESEARCH, vol. 30, no. 3, 1994, pages 187 - 228, XP002053037 *
SMITH U.: "Clinical and therapeutical aspects of the insulin resistance syndrome", CARDIOVASCULAR RISK FACTORS, vol. 3, no. 1, 1993, pages 67 - 73, XP002053038 *

Also Published As

Publication number Publication date
WO1998010786A2 (fr) 1998-03-19
AU4133997A (en) 1998-04-02

Similar Documents

Publication Publication Date Title
WO1998010786A3 (fr) Composition pharmaceutique pour le traitement du syndrome x de reaven
CA2235318A1 (fr) Procede de lutte contre les myiases des cheptels bovins et ovins et compositions pour la mise en oeuvre de ce procede
IL113812A0 (en) Copolymer-1, pharmaceutical compositions containing it and its use
ZA968956B (en) Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients
CA2179648A1 (fr) Compositions herbicides sous forme d'une solution d'azote et d'ether de diphenyle et leur procede d'utilisation
CA2370201A1 (fr) Compositions de soin pour la peau contenant une combinaison de principes actifs de soin pour la peau
ZA9710859B (en) Herbicidal compositions comprising N-[(4,6-dimethoxypyrimidin-2-yl)aminocarbonyl]-5-methylsulfonamidomethyl-2-alkoxycarbonylbenzenesulfonamides.
CA2241495A1 (fr) N,n',n'''-tris{2,4-bis¢(1-hydrocarbyloxy-2,2,6,6-tetramethylpiperidin- 4-yl)alkylamino!-s-triazin-6-yl}-3,3'-ethylenediiminodipropylamines, leurs isomeres et leurs derives pontes,utiles pour la stabilisation de compositions polymeriques
HUP9802822A3 (en) Halobenzimidazol derivatives, intermediates, preparation thereof and microbocide compositions containing these compounds as active ingredients
IL142531A0 (en) Cyclic peptide compound, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP9903336A3 (en) Substituted sulfonic acid n-[(aminoiminomethyl)phenylalkyl]-azaheterocyclamide compounds and pharmaceutical compositions containing the same
CA2163706A1 (fr) Derives amino-acides de paclitaxel
HUP9802865A3 (en) N-(substituted phenyl)-pyrazole-derivatives, preparation and use thereof, parasiticidal compositions containing these compounds as active ingredients
DE69401204T2 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
CA2215066A1 (fr) Sulfonylalcanoylamino hydroxyethylamino sulfonamides inhibiteurs de proteases de retrovirus
CA2355618A1 (fr) Suspensions de polyol/huile assurant la liberation prolongee des proteines
PL309282A1 (en) Application of 2-amino-6-n-propyl-amino- 4,5,6,7-tetrahydrobenzothiasole (pramipexol) as an antidepressant
DE69723728D1 (de) Totalsynthese des amino hip analogen von didemnin a
HUP9900365A3 (en) N-aryl-1,2,4-triazolin-5-on derivatives, preparation and use thereof, insecticide, arachnicide and nematocide compositions containing these compounds as active ingredients
EP1008345A4 (fr) Agents anti-allergiques
ZA978187B (en) Synergistic immunosuppressant composition containing a 2,2'-bi-1H-pyrrole compound.
EP0226842A3 (fr) 1,4-Naphtalènediones substitués, procédés pour leur préparation et compositions pharmaceutiques les contenant
WO1997028689A1 (fr) Composition herbicide
HUP9702479A3 (en) New polymorphous form of doxazosin-mesylate (form ii.), process for it's preparation and pharmaceutical compositions containing the same
CA2244782A1 (fr) Composition de nettoyage comprenant un ou plusieurs stabilisants des couleurs et un ou plusieurs tensioactifs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

WWE Wipo information: entry into national phase

Ref document number: 09254600

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998513454

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA